Biotech Values

[DewDiligence]

ABT posts solid 3Q14 results—57%* of sales from EM:

http://finance.yahoo.com/news/abbott-reports-third-quarter-2014-113100539.html

2014 non-GAAP EPS guidance is now $2.25-2.27 (vs the prior range of $2.19-2.29), growth of 12-13% vs 2013.

For ABT’s continuing operations, 57% of sales come from emerging markets, which is one of the highest EM footprints of any S&P 500 company.

*The branded-generics business being sold in the MYL deal (#msg-107440341) is now accounted for as a discontinued operation (although it is still included in ABT’s 2014 EPS guidance because the deal will not close until 2015).